FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2098419313> ?p ?o ?g. }

• W2098419313 endingPage "969" @default.
• W2098419313 startingPage "960" @default.
• W2098419313 abstract "The purpose of this study is to evaluate hospital mortality and major bleeding rates among patients receiving low molecular weight heparin (LMWH), unfractionated heparin (UFH), or both, and to investigate whether concomitant glycoprotein (GP) IIb/IIIa antagonists and coronary intervention affect patterns of use and outcomes with different heparins.With widespread use of glycoprotein (GP) IIb/IIIa inhibitors and invasive treatments, patients with high-risk acute coronary syndrome (ACS) may have a greater bleeding risk and may not gain additional benefit from LMWHs. The purpose of this study is to evaluate hospital mortality and major bleeding rates among patients receiving LMWH, UFH, or both, and to investigate whether concomitant GP IIb/IIIa antagonists and coronary intervention affect patterns of use and outcomes with different heparins.Data were analyzed from 28,445 patients with ACS; 21,287 had non-ST-segment elevation myocardial infarction or unstable angina and received LMWH or UFH.Fifty-one percent of patients received LMWH, 32% UFH, and 17% both. The lowest inhospital mortality and bleeding rates occurred with LMWH (2.7% and 1.8% vs UFH, 4.1% and 2.7%; all P < .0001). After multivariable analysis, LMWH was associated with lower inhospital mortality rates in patients not treated with GP IIb/IIIa antagonists, irrespective of whether they had a percutaneous coronary intervention (PCI) (odds ratio 0.77, 95% confidence interval 0.63-0.94 without PCI vs odds ratio 0.45, 95% confidence interval 0.21-0.98 with PCI). Excess bleeding occurred with PCI in LMWH-treated patients. Patients older than 75 years who received GP IIb/IIIa antagonists and any antithrombotic but not PCI had an increased risk of major bleeding (LMWH 14%, UFH 8.3%).In patients with non-ST-elevation ACS without GP IIb/IIIa antagonists, LMWH was associated with a lower mortality rate and more bleeding episodes in PCI-treated patients than UFH; no differences occurred with GP IIb/IIIa antagonists. Elderly patients managed medically with GP IIb/IIIa antagonists and either heparin had a very high major bleeding risk." @default.
• W2098419313 created "2016-06-24" @default.
• W2098419313 creator A5014449865 @default.
• W2098419313 creator A5027244910 @default.
• W2098419313 creator A5045302681 @default.
• W2098419313 creator A5047187243 @default.
• W2098419313 creator A5054783539 @default.
• W2098419313 creator A5055116135 @default.
• W2098419313 creator A5078295037 @default.
• W2098419313 creator A5086287744 @default.
• W2098419313 creator A5090147492 @default.
• W2098419313 date "2007-06-01" @default.
• W2098419313 modified "2023-10-13" @default.
• W2098419313 title "Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE)" @default.
• W2098419313 cites W1965274138 @default.
• W2098419313 cites W1978895866 @default.
• W2098419313 cites W1990962878 @default.
• W2098419313 cites W2026393945 @default.
• W2098419313 cites W2045713748 @default.
• W2098419313 cites W2062522570 @default.
• W2098419313 cites W2084522832 @default.
• W2098419313 cites W2095901832 @default.
• W2098419313 cites W2100410292 @default.
• W2098419313 cites W2114198397 @default.
• W2098419313 cites W2121251309 @default.
• W2098419313 cites W2134124835 @default.
• W2098419313 cites W2136351044 @default.
• W2098419313 cites W2136473335 @default.
• W2098419313 cites W2141192690 @default.
• W2098419313 cites W2142258305 @default.
• W2098419313 cites W2149599987 @default.
• W2098419313 cites W2157184686 @default.
• W2098419313 cites W2158336299 @default.
• W2098419313 cites W2315322366 @default.
• W2098419313 cites W2316460201 @default.
• W2098419313 cites W635046673 @default.
• W2098419313 doi "https://doi.org/10.1016/j.ahj.2007.03.035" @default.
• W2098419313 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17540196" @default.
• W2098419313 hasPublicationYear "2007" @default.
• W2098419313 type Work @default.
• W2098419313 sameAs 2098419313 @default.
• W2098419313 citedByCount "21" @default.
• W2098419313 countsByYear W20984193132012 @default.
• W2098419313 countsByYear W20984193132013 @default.
• W2098419313 countsByYear W20984193132016 @default.
• W2098419313 crossrefType "journal-article" @default.
• W2098419313 hasAuthorship W2098419313A5014449865 @default.
• W2098419313 hasAuthorship W2098419313A5027244910 @default.
• W2098419313 hasAuthorship W2098419313A5045302681 @default.
• W2098419313 hasAuthorship W2098419313A5047187243 @default.
• W2098419313 hasAuthorship W2098419313A5054783539 @default.
• W2098419313 hasAuthorship W2098419313A5055116135 @default.
• W2098419313 hasAuthorship W2098419313A5078295037 @default.
• W2098419313 hasAuthorship W2098419313A5086287744 @default.
• W2098419313 hasAuthorship W2098419313A5090147492 @default.
• W2098419313 hasConcept C126322002 @default.
• W2098419313 hasConcept C156957248 @default.
• W2098419313 hasConcept C164705383 @default.
• W2098419313 hasConcept C2776884760 @default.
• W2098419313 hasConcept C2777557582 @default.
• W2098419313 hasConcept C2777698277 @default.
• W2098419313 hasConcept C2777785093 @default.
• W2098419313 hasConcept C2778825682 @default.
• W2098419313 hasConcept C2779384505 @default.
• W2098419313 hasConcept C2780400711 @default.
• W2098419313 hasConcept C44249647 @default.
• W2098419313 hasConcept C45393284 @default.
• W2098419313 hasConcept C500558357 @default.
• W2098419313 hasConcept C71924100 @default.
• W2098419313 hasConceptScore W2098419313C126322002 @default.
• W2098419313 hasConceptScore W2098419313C156957248 @default.
• W2098419313 hasConceptScore W2098419313C164705383 @default.
• W2098419313 hasConceptScore W2098419313C2776884760 @default.
• W2098419313 hasConceptScore W2098419313C2777557582 @default.
• W2098419313 hasConceptScore W2098419313C2777698277 @default.
• W2098419313 hasConceptScore W2098419313C2777785093 @default.
• W2098419313 hasConceptScore W2098419313C2778825682 @default.
• W2098419313 hasConceptScore W2098419313C2779384505 @default.
• W2098419313 hasConceptScore W2098419313C2780400711 @default.
• W2098419313 hasConceptScore W2098419313C44249647 @default.
• W2098419313 hasConceptScore W2098419313C45393284 @default.
• W2098419313 hasConceptScore W2098419313C500558357 @default.
• W2098419313 hasConceptScore W2098419313C71924100 @default.
• W2098419313 hasIssue "6" @default.
• W2098419313 hasLocation W20984193131 @default.
• W2098419313 hasLocation W20984193132 @default.
• W2098419313 hasOpenAccess W2098419313 @default.
• W2098419313 hasPrimaryLocation W20984193131 @default.
• W2098419313 hasRelatedWork W2094160734 @default.
• W2098419313 hasRelatedWork W2210434259 @default.
• W2098419313 hasRelatedWork W2349195021 @default.
• W2098419313 hasRelatedWork W2355154366 @default.
• W2098419313 hasRelatedWork W2374819395 @default.
• W2098419313 hasRelatedWork W2385318150 @default.
• W2098419313 hasRelatedWork W2389079420 @default.
• W2098419313 hasRelatedWork W2393085073 @default.
• W2098419313 hasRelatedWork W2611470929 @default.
• W2098419313 hasRelatedWork W2962793371 @default.

• next